CompletedNCT02298985
Curcumin Added to Antipsychotic Treatment for Schizophrenia
About this title
Read the official source — NCT02298985Medication studyAges 18–60Israel
Understand this study
Who was this study for?
Listed age limits: 18 years to 60 years.
- Listed locations
- Beersheva and 1 more locationSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: January 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 38
- Sponsor
- Beersheva Mental Health Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Israel
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT02298985
- Official title
Show the full official title
Curcumin as add-on to Antipsychotic Treatment in Chronic Schizophrenia Patients: A Randomized, Double-Blind, Placebo-controlled Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Beersheva · Tirat Carmel
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Beersheva Mental Health Center, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Curcumin and placebo.
Who was this study for?
Listed age limits: 18 years to 60 years.
